Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GCAN - GammaCan International, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Benny-Rubin who wrote (4)	5/2/2005 10:52:09 AM
From: Biomaven	Read Replies (3) \| Respond to of 33

A couple of comments: 1. Normally a BB biotech company has no hope of getting a new drug approved because they simply don't have the resources. 2. The good news here is that they are dealing with an already approved product, so the path to regulatory approval is much easier. 3. The bad news is that because it is an existing product, they will likely always have something of a tough time enforcing their IP (they claim a use patent). So even assuming the drug works (which remains to be seen), I'm not sure how much money they will make. Production costs are very expensive indeed, meaning margins will be low. Personally not the sort of company I'd take a position in. Peter P.S. You will make no friends on SI biotech if you spam minor announcements about this company on all the biotech threads.